Bachir Dora, Hulin Anne, Huet Estelle, Habibi Anoosha, Nzouakou Ruben, El Mahrab Madjeline, Astier Alain, Galacteros Frédéric
Treatment Center of Sickle Cell Anemia, AP-HP, Hôpital Henri Mondor, Créteil, France.
Hemoglobin. 2007;31(4):417-25. doi: 10.1080/03630260701587745.
Hydroxyurea (HU) is useful for treating sickle cell anemia because of its ability to reduce some of the severe clinical events such as painful crises and acute chest syndrome. It may also reduce the need for blood transfusions and frequent hospitalizations and reduce mortality. Nevertheless, no consistent recommendations regarding its therapeutic schedule are defined. Our aim was to improve and validate a high performance liquid chromatography (HPLC) technique to measure HU and to study HU levels in serum and urine of sickle cell anemia patients and relate this to treatment efficacy and compliance. Thirty-seven patients received 1,128 +/- 333 mg of HU per day (8.0 to 28.0 mg/kg/day). Plasma and/or urine were sampled and HU was measured using an HPLC method coupled with UV detection. We validated a specific, sensitive assay with good reproducibility and linearity, and showed a positive relationship between plasma HU concentrations and time elapsed between oral HU intake and sampling. We observed plasma HU concentrations were positively correlated with change in mean corpuscular volume (MCV) before and during the treatment. No correlation was obtained between HU concentration and Hb F level.
羟基脲（HU）可用于治疗镰状细胞贫血，因为它能够减少一些严重的临床事件，如疼痛性危象和急性胸部综合征。它还可能减少输血需求和频繁住院，并降低死亡率。然而，关于其治疗方案尚无一致的建议。我们的目的是改进和验证一种高效液相色谱（HPLC）技术来测定HU，并研究镰状细胞贫血患者血清和尿液中的HU水平，并将其与治疗效果和依从性相关联。37名患者每天接受1128±333毫克的HU（8.0至28.0毫克/千克/天）。采集血浆和/或尿液样本，使用结合紫外检测的HPLC方法测定HU。我们验证了一种具有良好重现性和线性的特异性、灵敏性检测方法，并显示血浆HU浓度与口服HU摄入与采样之间的时间间隔呈正相关。我们观察到治疗前和治疗期间血浆HU浓度与平均红细胞体积（MCV）的变化呈正相关。HU浓度与Hb F水平之间未获得相关性。
